What we do Kobo Biotech Ltd is a manufacturer of active pharmaceutical ingredients (APIs) including diketene derivatives and biotechnological pharmaceutical intermediates such as pseudoephedrine and ephedrine. |
Founded in 1,992 |
Market share Not a market leader; operates in specialized pharmaceutical intermediate segments with recognized products and technical collaborations. |
Problem solved Provides essential chemical and biotech intermediates for pharmaceuticals, pigments, and pesticides sectors, addressing supply and quality needs. |
Top clients or who we serve Serves pharmaceutical companies, pigment and pesticide manufacturers; primarily B2B customers including multinational corporations via export contracts. |
Key management - |
Our journey and innovations Founded in 1992, renamed in 2020, developed technology for diketene recovery, expanded biotech division, received USFDA approval, and established long-term export contracts. |
Where we operate Primarily India with exports to international markets; has a subsidiary in Singapore for global reach. |
Top products or what we offer Diketene and derivatives (MMA, MAA), biotech intermediates (pseudoephedrine, ephedrine) with FDA-approved manufacturing facilities. |
Top brands MMA, MAA, DEA, EEAA, Aralydes - reputable chemical intermediates; pharmaceutical biotech products with growing export presence. |
Raw materials needed Basic chemicals for diketene production and molasses for biotech intermediates manufacturing. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue is largely cyclical, tied to pharmaceutical intermediate demand and export contracts. |
Our industry position Niche player with technical collaborations; not market leader but recognized for quality and innovation in pharma intermediates. |
Financial highlights FY 2023 revenue approximately Rs. 1.52 crore with EBITDA loss of Rs. 148.13 lakh, loss after tax Rs. 555.34 lakh reflecting financial challenges. |
Geographical revenue split Domestic revenue approx. Rs. 5.49 crore; exports approx. Rs. 4.83 crore as per FY 2014 data. |
Order book - |
Whats driving growth USFDA approvals, biotech capacity expansions, long-term export contracts, and product innovation in high-value intermediates. |
Our future plans Launch of high value-added pharmaceutical intermediates, enhance biotech production capabilities, and seek entry into regulated markets. |
Our green promise - |
Our people and values Operates with a small senior management team emphasizing compliance and corporate governance; low employee base with no significant disclosures. |
Key challenges ahead Regulatory hurdles, financial losses, operational challenges at Solapur plant, litigation risks, and competitive pharmaceutical supply markets. |
Interesting facts First in Andhra Pradesh awarded Best New Product; developed unique diketene recovery technology; underwent significant ownership changes. |
Risks and strategy Facing regulatory and financial issues; strategy includes technological upgrades, export diversification, and compliance enhancement. |
